ZURICH, June 22 (Reuters) - Novartis aims to help manufacture more than 50 million doses of BioNTech's COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union's drug regulator approved the bottling plant. (Reporting by John Miller Editing by Chris Reese)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
91.94 CHF | +0.22% | -2.08% | +8.33% |
11:15am | Novartis: positive phase III results in C3G | CF |
10:15am | Novartis: presented results for kidney disease | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.33% | 205B | |
+38.51% | 727B | |
+31.83% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
-5.69% | 203B | |
+6.19% | 164B | |
+0.31% | 164B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021